Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma

Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus... BAC SYMPOSIUM Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma Mark G. Kris, MD,* Giuseppe Giaccone, MD,† Angela Davies, MD,‡ Masahiro Fukuoka, MD,§ David H. Garfield, MD, Jacek Jassem, MD,¶ Elisabeth A. Quoix, MD,# Alan B. Sandler, MD,** Giorgio V. Scagliotti, MD,†† Jan P. Van Meerbeeck, MD, PhD,‡‡ and Howard West, MD§§ Key Words: Adenocarcinoma, Bronchioloalveolar carcinoma, Introduction: Bronchioloalveolar carcinoma (BAC) is a subtype of Epidermal growth factor receptor, Gefitinib, Erlotinib. adenocarcinoma of the lung with unique pathological, clinical, and (J Thorac Oncol. 2006;1: S32–S36) molecular characteristics. Methods: This consensus conference group reviewed studies per- formed specifically in BAC and data from patients with BAC who ronchioloalveolar carcinoma (BAC) may be distinguished were included in clinical trials of all non–small-cell lung cancer Bfrom other adenocarcinomas of the lung by unique his- (NSCLC) subtypes. tology, radiology, molecular biology, and clinical course. It is Results: Although BAC as defined by the World Health Organiza- thought that the course of patients with BAC is more indolent tion represents less than 5% of adenocarcinomas, as many as 20% of than in persons with other non–small-cell lung cancer adenocarcinomas have BAC features. These latter tumors are more http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma

West, Howard
Journal of Thoracic Oncology , Volume 1 – Nov 1, 2006
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/systemic-therapy-of-bronchioloalveolar-carcinoma-colon-results-of-the-Kb0hKY6mwO

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

BAC SYMPOSIUM Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma Mark G. Kris, MD,* Giuseppe Giaccone, MD,† Angela Davies, MD,‡ Masahiro Fukuoka, MD,§ David H. Garfield, MD, Jacek Jassem, MD,¶ Elisabeth A. Quoix, MD,# Alan B. Sandler, MD,** Giorgio V. Scagliotti, MD,†† Jan P. Van Meerbeeck, MD, PhD,‡‡ and Howard West, MD§§ Key Words: Adenocarcinoma, Bronchioloalveolar carcinoma, Introduction: Bronchioloalveolar carcinoma (BAC) is a subtype of Epidermal growth factor receptor, Gefitinib, Erlotinib. adenocarcinoma of the lung with unique pathological, clinical, and (J Thorac Oncol. 2006;1: S32–S36) molecular characteristics. Methods: This consensus conference group reviewed studies per- formed specifically in BAC and data from patients with BAC who ronchioloalveolar carcinoma (BAC) may be distinguished were included in clinical trials of all non–small-cell lung cancer Bfrom other adenocarcinomas of the lung by unique his- (NSCLC) subtypes. tology, radiology, molecular biology, and clinical course. It is Results: Although BAC as defined by the World Health Organiza- thought that the course of patients with BAC is more indolent tion represents less than 5% of adenocarcinomas, as many as 20% of than in persons with other non–small-cell lung cancer adenocarcinomas have BAC features. These latter tumors are more

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Nov 1, 2006

There are no references for this article.